Related Experiment Videos
Visual prognosis in giant cell arteritis
P D Aiello1, J C Trautmann, T J McPhee
1Department of Ophthalmology, Mayo Clinic, Rochester, MN 55905.
Ophthalmology
|April 1, 1993
Summary
Giant cell arteritis (GCA) rarely causes vision loss after glucocorticoid therapy begins. Most visual deficits in GCA patients occur before treatment, with a low probability of further loss after therapy initiation.
Area of Science:
- Ophthalmology
- Rheumatology
- Internal Medicine
Background:
- Giant cell arteritis (GCA) is a systemic vasculitis that can lead to irreversible vision loss.
- Early diagnosis and treatment are crucial to prevent visual complications.
Purpose of the Study:
- To evaluate the visual prognosis in patients diagnosed with giant cell arteritis over a 5-year period.
- To determine the incidence and timing of visual loss in relation to glucocorticoid therapy initiation.
Main Methods:
- Retrospective review of medical records for patients diagnosed with GCA at the Mayo Clinic.
- Follow-up data collected 5 years after initial diagnosis to assess visual status.
Main Results:
- Out of 245 patients, 34 (14%) experienced permanent vision loss due to GCA.
- Visual deficit occurred before glucocorticoid therapy in 32 patients.
- The probability of vision loss developing after initiating glucocorticoid treatment was 1%; additional loss was 13% in those with pre-existing deficits.
Conclusions:
- The development or progression of visual loss is infrequent after the initiation of glucocorticoid therapy for GCA.
- Prompt treatment with glucocorticoids is effective in preserving vision in most GCA patients.